The global market for Friedreich’s Ataxia drugs is projected to experience significant growth, reaching a value of US$ 3.49 billion by 2034. This growth is driven by increased investments in disease-modifying treatments and gene therapy, as well as supportive initiatives from governments and non-profit organizations. The market is expected to be dominated by North America, with a projected market share of 36.7% by 2034.